Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy 
for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan

Miyazaki,Akira; Miyake,Hideaki; Harada,Ken‑Ichi; Inoue,Taka‑Aki; Fujisawa,Masato

doi:10.3892/mco.2015.487

May-2015 Volume 3 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2015 Volume 3 Issue 3

Full Size Image

Article

Prognostic outcome in patients treated with tyrosine kinase inhibitors as first-line molecular-targeted therapy for metastatic renal cell carcinoma: Experience in real-world clinical practice in Japan

Authors:
- Akira Miyazaki
- Hideaki Miyake
- Ken‑Ichi Harada
- Taka‑Aki Inoue
- Masato Fujisawa
View Affiliations / Copyright

Affiliations: Division of Urology, Kobe University Graduate School of Medicine, Kobe, Hyogo 650‑0017, Japan, Department of Urology, Hyogo Cancer Center, Akashi, Hyogo 673-0021, Japan
Pages: 601-606
|
Published online on: January 19, 2015

https://doi.org/10.3892/mco.2015.487
Expand metrics +

Abstract

The aim of this study was to evaluate the oncological efficacy of tyrosine kinase inhibitors (TKIs) as first‑line molecular‑targeted therapy for Japanese patients with metastatic renal cell carcinoma (mRCC) in a routine clinical setting. This study included a total of 271 consecutive Japanese patients with TKI‑naive mRCC, including 172 patients who received sorafenib and 99 who received sunitinib for ≥2 months as a first‑line molecular‑targeted agent. the prognostic outcomes of these patients were retrospectively assessed. During the observation period (median, 19 months), 126 patients (46.5%) succumbed to the disease and the median overall survival (OS) for the entire cohort was 33.1 months. The univariate analysis identified the Memorial Sloan‑Kettering Cancer Center (MSKCC) classification, C‑reactive protein (CRP) level, lymph node metastasis, bone metastasis, liver metastasis, histological subtype and sarcomatoid characteristics as significant predictors of OS. Of these factors, only the MSKCC classification, CRP level and liver metastasis were found to be independently associated with OS in the multivariate analysis. Furthermore, there were significant differences in OS according to the positivity for these 3 independent risk factors (i.e., negative for all factors vs. positive for a single factor vs. positive for 2 or 3 factors). These findings suggest that the introduction of TKIs as first‑line molecular‑targeted agents resulted in favorable cancer control outcomes in Japanese mRCC patients and that the prognosis of these patients may be stratified by 3 potential parameters, including the MSKCC classification, CRP level and liver metastasis.

View Figures

View References

1	Parton M, Gore M and Eisen T: Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol. 24:5584–5592. 2006. View Article : Google Scholar : PubMed/NCBI
2	Figlin R, Sternberg C and Wood CG: Novel agents and approaches for advanced renal cell carcinoma. J Urol. 188:707–715. 2012. View Article : Google Scholar : PubMed/NCBI
3	Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
4	Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
5	Rini BI, Escudier B, Tomczak P, et al: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 378:1931–1939. 2011. View Article : Google Scholar : PubMed/NCBI
6	Motzer RJ, Hutson TE, Cella D, et al: Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 369:722–731. 2013. View Article : Google Scholar : PubMed/NCBI
7	Patard JJ, Pignot G, Escudier B, et al: ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease. Eur Urol. 60:684–690. 2011. View Article : Google Scholar : PubMed/NCBI
8	Gore ME, Szczylik C, Porta C, et al: Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol. 10:757–763. 2009. View Article : Google Scholar : PubMed/NCBI
9	Harshman LC, Xie W, Bjarnason GA, et al: Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol. 13:927–935. 2012. View Article : Google Scholar : PubMed/NCBI
10	Beck J, Procopio G, Bajetta E, et al: Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol. 22:1812–1823. 2011. View Article : Google Scholar : PubMed/NCBI
11	Heng DY, Xie W, Regan MM, et al: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar : PubMed/NCBI
12	Choueiri TK, Duh MS, Clement J, et al: Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review. BJU Int. 105:1247–1254. 2010. View Article : Google Scholar : PubMed/NCBI
13	Miyake H, Miyazaki A, Harada K, et al: Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. Med Oncol. 31:9782014. View Article : Google Scholar : PubMed/NCBI
14	Motzer RJ, Bacik J, Murphy BA, et al: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
15	Ainsworth NL, Lee JS and Eisen T: Impact of anti-angiogenic treatments on metastatic renal cell carcinoma. Expert Rev Anticancer Ther. 9:1793–1805. 2009. View Article : Google Scholar : PubMed/NCBI
16	You D, Jeong IG, Ahn JH, et al: The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy. J Urol. 185:54–59. 2011. View Article : Google Scholar : PubMed/NCBI
17	Beuselinck B, Vano YA, Oudard S, et al: Prognostic impact of baseline serum C-reactive protein in patients with metastatic renal cell carcinoma (RCC) treated with sunitinib. BJU Int. 114:81–89. 2014. View Article : Google Scholar : PubMed/NCBI
18	Kwon WA, Cho IC, Yu A, et al: Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib. Ann Surg Oncol. 20:4397–4404. 2013. View Article : Google Scholar : PubMed/NCBI
19	Miyake H, Kusuda Y, Harada K, et al: Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma. Int J Clin Oncol. 18:81–86. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hudes G, Carducci M, Tomczak P, et al: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar : PubMed/NCBI